Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Rang in aandelen #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Aandeelprijs
$0.04959193
Laatst gesynchroniseerd: 2025-03-17
Marktkapitalisatie
$79.94M
Verandering (1 dag)
13.49%
Verandering (1 jaar)
0.00%
Land
SE
Handel Abliva AB (publ) (ABLI)

Categorie

Koersgeschiedenis voor Abliva AB (publ) (ABLI)
Hoogste slotkoers: $0.04 op 2025-03-01

Laagste slotkoers: $0.44 op 2008-10-01
Koersgeschiedenis van Abliva AB (publ) van 2008 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2025 83.38%
2024 -0.37%
2023 44.87%
2022 -73.02%
2021 -34.26%
2020 -30.47%
2019 -20.24%
2018 -46.40%
2017 4.60%
2016 -62.61%
2015 -86.83%
2014 208.88%
2013 -8.57%
2012 59.62%
2011 -55.60%
2010 208.76%
2009 91.09%
2008 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH